Biotechnology
Biogen beats expectations, hikes outlook as Alzheimer’s drug Leqembi and other new products gain traction
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company’s cost cuts showed progress and sales of its breakthrough Alzheimer’s drug, Leqembi, and […]
Read More
Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market
Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a “competitive environment” for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025. The biotech company now expects 2024 product revenue to come in between $3 billion to $3.5 […]
Read More
Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says
The newly FDA approved Alzheimer’s treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on Tuesday, November 7, 2023. Hannah Yoon | The Washington Post | Getty Images The breakthrough Alzheimer’s drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term, […]
Read More
Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs
Kena Betancur | Corbis News | Getty Images Pfizer on Thursday reported second-quarter revenue and adjusted earnings that blew past expectations and raised its full-year outlook, benefiting from its broad cost-cutting program, better-than-expected sales of its Covid antiviral pill Paxlovid and strong non-Covid product sales. The company now expects to book adjusted earnings of $2.45 to $2.65 […]
Read More
Older GLP-1 drug from Novo Nordisk may slow Alzheimer’s disease progression by protecting the brain, study says
A box of the drug Victoza, made by Novo Nordisk Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020. George Frey | Reuters An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer’s disease by protecting patients’ brains, according to data […]
Read More
Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda
The exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb. 5, 2024. Spencer Platt | Getty Images Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology […]
Read More
Swiss pharma giant Roche to accelerate Wegovy rival drugs after positive trial data
Sopa Images | Lightrocket | Getty Images Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. The company’s two obesity drug candidates are progressing to the next phase of trials and could come to market within the next few years, […]
Read More
European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai
European drug regulators on Friday rejected the Alzheimer’s treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The European Commission, the EU’s executive body, has a final say in Leqembi’s approval. But it almost always follows the drug regulator’s recommendations. […]
Read More
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Friday reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance as the drugmaker moves to slash costs. The pharmaceutical giant raised its […]
Read More
Novo Nordisk’s Wegovy wins EU backing for reducing heart risks
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Hollie Adams | Reuters Novo Nordisk’s blockbuster Wegovy weight loss drug has received backing from the European Union’s medical regulator to expand the medicine’s use to include reducing the rise of serious heart events in overweight and obese adults. The Danish […]
Read More